Who needs to be screened for primary aldosteronism?
Copyright © 2023 Formosan Medical Association. Published by Elsevier B.V. All rights reserved..
The prevalence of patients with primary aldosteronism (PA) is about 5%-15% in hypertensive patients, and it is common cause of secondary hypertension in clinical practice. Two major causes of PA are noted, namely bilateral adrenal hyperplasia and aldosterone-producing adenoma, and the general diagnosis is based on three steps: (1) screening, (2) confirmatory testing, and (3) subtype differentiation (Figure 1). The recommendation for screening patients is at an increased risk of PA, here we focus on which patients should be screened for PA, not only according to well-established guidelines but for potential patients with PA. We recommend screening for 1) patients with resistant or persistent hypertension, 2) hypertensive patients with hypokalemia (spontaneous or drug-induced), 3) young hypertensive patients (age <40 years), and 4) all hypertensive patients with a history of PA in first-degree relatives. Moreover, we suggest screening for 1) hypertensive patients themselves or first-degree relatives with early target organ damage, such as stroke and other diseases, 2) all hypertensive patients with a concurrent adrenal incidentaloma, 3) hypertensive patients with obstructive sleep apnea, 4) hypertensive patients with atrial fibrillation unexplained by structural heart defects and/or other conditions resulting in the arrhythmia, 5) hypertensive patients with anxiety and other psychosomatic symptoms, and 6) hypertensive patients without other comorbidities to maintain cost-effectiveness.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:123 Suppl 2 |
|---|---|
| Enthalten in: |
Journal of the Formosan Medical Association = Taiwan yi zhi - 123 Suppl 2(2024) vom: 04. März, Seite S82-S90 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Huang, Wei-Chieh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aldosterone renin ratio |
|---|
| Anmerkungen: |
Date Completed 12.03.2024 Date Revised 12.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jfma.2023.08.021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361319347 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361319347 | ||
| 003 | DE-627 | ||
| 005 | 20240312233201.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jfma.2023.08.021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM361319347 | ||
| 035 | |a (NLM)37633770 | ||
| 035 | |a (PII)S0929-6646(23)00335-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Huang, Wei-Chieh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Who needs to be screened for primary aldosteronism? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.03.2024 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Formosan Medical Association. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a The prevalence of patients with primary aldosteronism (PA) is about 5%-15% in hypertensive patients, and it is common cause of secondary hypertension in clinical practice. Two major causes of PA are noted, namely bilateral adrenal hyperplasia and aldosterone-producing adenoma, and the general diagnosis is based on three steps: (1) screening, (2) confirmatory testing, and (3) subtype differentiation (Figure 1). The recommendation for screening patients is at an increased risk of PA, here we focus on which patients should be screened for PA, not only according to well-established guidelines but for potential patients with PA. We recommend screening for 1) patients with resistant or persistent hypertension, 2) hypertensive patients with hypokalemia (spontaneous or drug-induced), 3) young hypertensive patients (age <40 years), and 4) all hypertensive patients with a history of PA in first-degree relatives. Moreover, we suggest screening for 1) hypertensive patients themselves or first-degree relatives with early target organ damage, such as stroke and other diseases, 2) all hypertensive patients with a concurrent adrenal incidentaloma, 3) hypertensive patients with obstructive sleep apnea, 4) hypertensive patients with atrial fibrillation unexplained by structural heart defects and/or other conditions resulting in the arrhythmia, 5) hypertensive patients with anxiety and other psychosomatic symptoms, and 6) hypertensive patients without other comorbidities to maintain cost-effectiveness | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Aldosterone renin ratio | |
| 650 | 4 | |a Hypertension | |
| 650 | 4 | |a Primary aldosteronism | |
| 650 | 4 | |a Screen | |
| 700 | 1 | |a Liu, Feng-Hsuan |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Hao-Min |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Yi-Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yen-Ta |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, Tai-Shuan |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yen-Hung |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Vin-Cent |e verfasserin |4 aut | |
| 700 | 1 | |a Kao, Hsien-Li |e verfasserin |4 aut | |
| 700 | 1 | |a Jia-Yin Hou, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Kwan-Dun |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Szu-Tah |e verfasserin |4 aut | |
| 700 | 1 | |a Er, Leay Kiaw |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the Formosan Medical Association = Taiwan yi zhi |d 1992 |g 123 Suppl 2(2024) vom: 04. März, Seite S82-S90 |w (DE-627)NLM012627941 |x 0929-6646 |7 nnns |
| 773 | 1 | 8 | |g volume:123 Suppl 2 |g year:2024 |g day:04 |g month:03 |g pages:S82-S90 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jfma.2023.08.021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 123 Suppl 2 |j 2024 |b 04 |c 03 |h S82-S90 | ||